Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a ...
Fierce Biotech

Eli Lilly sidelines midstage prospect in another pain pipeline pivot

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

Dividend Roundup: Visa, Eli Lilly, Ford, Wells Fargo, and more

This week's dividend activity included increased payouts from Visa ( V) and Marathon Petroleum ( MRC) as well as declarations ...

20% Upside For Eli Lilly Stock?

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Chipotle

The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...